Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modern diagnostics in acute leukemias.

Torsten Haferlach1, Wolfgang Kern, Susanne Schnittger

  • 1Laboratory for Leukemia Diagnostics, Medical Department III, University Hospital Grosshadern, Ludwig-Maximilians-University, Marchioninistreet 15, 81377 Munich, Germany. torsten.haferlach@mll-online.com

Critical Reviews in Oncology/Hematology
|October 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.

BMC pharmacology & toxicology·2020
Same author

Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.

European journal of haematology·2017
Same author

Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.

The American journal of case reports·2017
Same author

Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia.

British journal of haematology·2016
Same author

BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance.

British journal of haematology·2016
Same author

Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia.

Genes, chromosomes & cancer·2015
Same journal

Remodeling the Immune Microenvironment: Engineering IL-2 Variants to Overcome Clinical Bottlenecks in PD-1 Inhibitor plus Chemotherapy.

Critical reviews in oncology/hematology·2026
Same journal

Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted Management.

Critical reviews in oncology/hematology·2026
Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026
Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026
Same journal

Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

Critical reviews in oncology/hematology·2026
Same journal

Gene fusions in non-small cell lung carcinoma (NSCLC): Expert perspectives and practical considerations for routine testing.

Critical reviews in oncology/hematology·2026
See all related articles

Accurate diagnosis of acute leukemias requires a comprehensive panel of tests. These methods are crucial for classifying subtypes, guiding treatment, and monitoring minimal residual disease (MRD) for improved patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute leukemias are diverse diseases with outcomes heavily influenced by subtype-specific biology.
  • Advances in understanding disease biology have led to improved patient survival rates.

Purpose of the Study:

  • To emphasize the necessity of comprehensive diagnostic approaches in acute leukemias.
  • To highlight the role of diagnostics in classification, treatment decisions, and minimal residual disease monitoring.

Main Methods:

  • Cytomorphology
  • Cytochemistry
  • Multiparameter flow cytometry (MFC)
  • Cytogenetics
  • Fluorescence in situ hybridization (FISH)
  • Molecular genetic methods

Related Experiment Videos

Main Results:

  • A combination of diagnostic techniques is essential for accurate acute leukemia diagnosis.
  • Diagnostic results are critical for tailoring individual treatment strategies.
  • Monitoring minimal residual disease (MRD) using specific markers guides further treatment adjustments.

Conclusions:

  • Comprehensive diagnostic panels are indispensable for the accurate classification and management of acute leukemias.
  • Individualized treatment and effective MRD monitoring rely on robust diagnostic data.
  • Continued advancements in diagnostic methods are key to improving patient outcomes in acute leukemia.